This article is informational only. It summarizes publicly documented pharmacopeial monograph requirements and regulatory guidance as they apply to mineral excipients. It does not certify, test, or make any claim about the compliance status of any specific PlaxRaw shipment, and it is not a substitute for a buyer’s own regulatory due diligence, monograph verification, and testing program. Always verify current requirements directly against the applicable pharmacopeial monograph and your own compliance documentation.
“Pharmacopeial-grade purity” sounds like a single pass/fail line on a certificate, but for a mineral excipient like calcium carbonate or talc it is actually a stack of separate, monograph-specific tests — identity, assay, acid-insoluble matter, particle size, and elemental impurities — and a buyer who only checks one of them can still end up with material that fails the others.
Root Causes
The USP-NF Calcium Carbonate monograph sets an assay requirement of not less than 98.0% and not more than 100.5% calcium carbonate, calculated on the substance dried at 200°C for 4 hours — a specific, testable identity and purity window, not a general “high purity” description. The USP-NF Talc monograph carries its own separate specifications, including a minimum purity threshold, a maximum acid-insoluble substances limit, and a particle-size ceiling on the fraction of oversize material — each of these is a distinct test a supplier’s certificate of analysis has to actually report against, not a single combined purity number.
Elemental impurity testing has changed substantially in the last decade. USP General Chapter <231> Heavy Metals — a roughly century-old colorimetric precipitation test — is being phased out of individual monographs in favor of USP General Chapters <232> Elemental Impurities–Limits and <233> Elemental Impurities–Procedures, which are harmonized with the ICH Q3D Guideline for Elemental Impurities. Under this framework, arsenic, cadmium, mercury, and lead are assessed in every case as the four most toxic and best-understood elements, alongside up to twelve additional elements depending on the drug product’s route of administration and the excipient’s likely contribution. This is a materially different test than the old colorimetric method: <232>/<233> require element-specific analytical methods such as ICP-MS rather than a single visual color-match threshold, and the permitted daily exposure (PDE) limits are route-of-administration-specific — the same raw material can be acceptable for an oral solid-dosage use case and unacceptable for a parenteral or inhalation one, because the PDE tiers differ by route, not by material.
A further documented gap is that USP-NF, Ph. Eur., and BP monographs for the same nominal material are not always numerically identical. The pharmacopeial harmonization process (PDG) has aligned many excipient monographs, but not every parameter in every monograph, so a lot that is in spec against one pharmacopoeia’s numeric limit is not automatically in spec against another’s — a buyer registering the same formulation in multiple markets cannot assume one certificate satisfies all three.
What This Means for Raw Material Selection
Request identity and assay data referenced against the specific pharmacopeial monograph and revision your registration relies on — USP-NF, Ph. Eur., or BP — rather than accepting an unspecified “USP grade” or “pharma grade” label on a certificate of analysis. For elemental impurities, ask specifically whether the supplier’s data is generated under the current <232>/<233> (ICH Q3D) framework or the legacy <231> colorimetric method, since the latter is being retired from monographs and does not report the same element-specific, route-of-administration-adjusted result. Confirm which route-of-administration PDE tier your finished-dose application falls under before evaluating whether a given elemental result is acceptable — a numeric result that clears the oral-route threshold is not automatically acceptable for a stricter route class. Finally, treat any certificate of analysis as a starting point rather than a final answer: request the actual test method reference and the monograph version cited, since monograph revisions (including the ongoing USP Talc monograph modernization) can change what a compliant result looks like over time.
Sources: USP-NF General Chapter <232> Elemental Impurities–Limits and General Chapter <233> Elemental Impurities–Procedures; ICH Q3D Guideline for Elemental Impurities; FDA Guidance for Industry, “Elemental Impurities in Drug Products”; USP-NF Calcium Carbonate monograph; USP-NF Talc monograph and USP “FAQs: Modernization of the USP Talc Monograph” (usp.org). This article does not verify or certify compliance with any specific pharmacopeial monograph for any PlaxRaw product.
